07.04.2026 16:10
Plus Therapeutics (PSTV) opened the session at $3.17, marking a 4.80% decline. The American Medical Association (AMA) has bestowed approval on the CNSide CPT code 0640U, a move that paves the way for clearer reimbursement and broader commercial uptake of the company’s amyloid‑targeting diagnostic platform.
By securing this AMA‑endorsed code, CNSide gains a concrete billing pathway, positioning Plus Therapeutics to accelerate its U.S. clinical rollout. The new CPT designation also sharpens tracking of diagnostic utilizations, bolstering revenue prospects as adoption expands across healthcare providers.
The recent code endorsement underscores the growing validation of CNSide’s technology within the medical community, suggesting that the company’s diagnostic solutions are poised for larger market penetration and sustained growth in the coming months.
